BRIVADEP Canadian Trademark Information
Pharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, stroke, cancer, respiratory diseases, auto-immune diseases, solid organ transplant rejection; pharmaceutical preparations for human use relating to metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents.
Perfect for these industries
Words that describe this mark
pharmaceutical preparations human use treatment prevention obesity diabetes incontinence cardiovascular diseases stroke cancer respiratory diseases autoimmune diseases solid organ transplant rejection pharmaceutical preparations human use relating metabolic disorders
Abandonment Notice!
On Wednesday, March 13, 2019,
status on the BRIVADEP
trademark changed to Interruption of proceeding.
Apply Now for this name starting at $449!
CAUTION: Although Canada registration for this particular filing is inactive,
the mark may still enjoy common law rights, or may have been applied for again in a separate application.
Further research may be warranted to determine where this mark is truly abandoned in commerce.
On Tuesday, February 17, 2015, a canadian trademark registration was filed for
BRIVADEP by Bristol-Myers Squibb Company ( *********, **********, ***** ****.
The Canadian IP office has given the trademark application number of
1715641.
The current status of this trademark filing is Interruption of proceeding.
The correspondent listed for
BRIVADEP is
GOWLING WLG (CANADA) LLP of *********, **********, ***** ****
The BRIVADEP
trademark is filed in the description of
Pharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, stroke, cancer, respiratory diseases, auto-immune diseases, solid organ transplant rejection; pharmaceutical preparations for human use relating to metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents.
.
100% Satisfaction Guarantee
protect your valuable brand now.
Classification Information